구조모아 (StructureMoa)항암 chemical structure spider web
방문Intravenous immunoglobulin (IVIG)(Sanofi)은 Kawasaki Disease 표적 치료제로, Kawasaki Disease 영역에서 개발·상용화 중입니다. 작용기전: targeting immune checkpoints - regulatory pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: 51.9% (ClinicalTrials.gov NCT05041257). 차별점: unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Kawasaki Disease
Kawasaki Disease
Recruiting
2026-09-02
Data Confidence · Low
Development Signal · Emerging
CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Beyon
humanized monoclonal antibody and immune checkpoint inhibitor used for the treatment of advanced non-small ce
unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide
targeting immune checkpoints - regulatory pathway
immune-mediated subtypes remain inconclusive and warrant further research with biologically stratified, adequately powered trials
apoptosis and pyroptosis, decreased inflammatory factors, enhanced antioxidant capacity, and alleviated DNA damage
Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia-Shigella, and Actin
resistance to intravenous immunoglobulin (IVIG) remains a significant clinical challenge
구조화 데이터
mouse
pd
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Intravenous immunoglobulin (IVIG)(Sanofi)은 Kawasaki Disease 표적 치료제로, Kawasaki Disease 영역에서 개발·상용화 중입니다. 작용기전: targeting immune checkpoints - regulatory pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: 51.9% (ClinicalTrials.gov NCT05041257). 차별점: unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Kawasaki Disease
Kawasaki Disease
Recruiting
2026-09-02
Data Confidence · Low
Development Signal · Emerging
CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Beyon
humanized monoclonal antibody and immune checkpoint inhibitor used for the treatment of advanced non-small ce
unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide
targeting immune checkpoints - regulatory pathway
immune-mediated subtypes remain inconclusive and warrant further research with biologically stratified, adequately powered trials
apoptosis and pyroptosis, decreased inflammatory factors, enhanced antioxidant capacity, and alleviated DNA damage
Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia-Shigella, and Actin
resistance to intravenous immunoglobulin (IVIG) remains a significant clinical challenge
구조화 데이터
mouse
pd
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.